Dr. Emmanuel S. Antonarakis, MD

Dr. Antonarakis practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Antonarakis' NPI, 1568528768, was assigned on December 29, 2006. Dr. Antonarakis holds Maryland license D66129.

Dr. Antonarakis' primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Antonarakis' primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Dr. Antonarakis is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Antonarakis to 1 more hospital, 4 medical groups, 3 group practices and clinics, 1 dialysis center and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Antonarakis practices, 8 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Antonarakis' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Antonarakis is licensed in Maryland.

CMS data shows 328 Medicare services from Dr. Antonarakis across 4 procedure codes in 2024, for 100 Medicare patients. Medicare paid $29,808 for them.

CMS counts 100 Medicare patients who saw Dr. Antonarakis in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have cancer, and 63% have high blood pressure. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Antonarakis' median patient age at 73, with 8% women.

In 2024, Dr. Antonarakis wrote 646 Medicare Part D claims for 69 patients. 65% of them were for generic drugs. CMS names the drug for 503 of them, across 16 drugs with 11 or more claims each, at $2,838,662 in total drug cost. In 2023, CMS named 293 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Antonarakis for performance year 2024, reported as part of a group. Dr. Antonarakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Antonarakis as offering telehealth.

Dmand AI links Dr. Antonarakis to 2 clinical trials. Conditions studied include Prostatic Neoplasms and Prostatic Diseases. Sanofi sponsors the most, 2. Open Payments lists research payments to Dr. Antonarakis that name 5 trials.

CMS Open Payments shows 281 general payments to Dr. Antonarakis from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Merck Sharp & Dohme Corporation paid the most, $79,919. It also lists 15 research payments totaling $268,817 from 2016 to 2019, naming 5 clinical trials.